Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer

• Published in: Cell death & disease 2022-09, Vol.13 (9), p.754-754, Article 754
• Main Authors: Lv, Shidong, Wu, Zeyu, Luo, Mayao, Zhang, Yifan, Zhang, Jianqiang, Pascal, Laura E., Wang, Zhou, Wei, Qiang
• Format: Article
• Language: English
• Subjects: 13/2; 13/31; 13/89; 38/91; 45/15; 631/154/555; 631/67/1459; 64/60; 82/58; Androgen receptors; Antibodies; Antigens, Nuclear - genetics; Antigens, Nuclear - metabolism; Antiparasitic agents; Antitumor activity; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Culture; Cell cycle; Cell death; Cell proliferation; Chromatin; DNA Breaks, Double-Stranded; DNA damage; DNA End-Joining Repair; DNA Repair; Forkhead protein; Hepatocyte Nuclear Factor 3-alpha - drug effects; Hepatocyte Nuclear Factor 3-alpha - metabolism; Homologous recombination; Homologous recombination repair; Humans; Immunology; Intracellular signalling; Ivermectin; Ivermectin - pharmacology; Ivermectin - therapeutic use; Kinases; Ku Autoantigen - drug effects; Ku Autoantigen - metabolism; Life Sciences; Male; Non-homologous end joining; Prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Proteomes; Tumor cells; Xenografts
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-022-05182-0

Ivermectin is a widely used antiparasitic drug and shows promising anticancer activity in various cancer types. Although multiple signaling pathways modulated by ivermectin have been identified in tumor cells, few studies have focused on the exact target of ivermectin. Herein, we report the pharmacological effects and targets of ivermectin in prostate cancer. Ivermectin caused G0/G1 cell cycle arrest, induced cell apoptosis and DNA damage, and decreased androgen receptor (AR) signaling in prostate cancer cells. Further in vivo analysis showed ivermectin could suppress 22RV1 xenograft progression. Using integrated omics profiling, including RNA-seq and thermal proteome profiling, the forkhead box protein A1 (FOXA1) and non-homologous end joining (NHEJ) repair executer Ku70/Ku80 were strongly suggested as direct targets of ivermectin in prostate cancer. The interaction of ivermectin and FOXA1 reduced the chromatin accessibility of AR signaling and the G0/G1 cell cycle regulator E2F1, leading to cell proliferation inhibition. The interaction of ivermectin and Ku70/Ku80 impaired the NHEJ repair ability. Cooperating with the downregulation of homologous recombination repair ability after AR signaling inhibition, ivermectin increased intracellular DNA double-strand breaks and finally triggered cell death. Our findings demonstrate the anticancer effect of ivermectin in prostate cancer, indicating that its use may be a new therapeutic approach for prostate cancer.